ReviewHeliyon2023

An extension of cancer immunotherapy with dostarlimab, the PD1-PD L1 pathway blocker.

Sitangshu Sekhar Biswas et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.